Passage Bio, Inc.

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Their portfolio spans pediatric and adult CNS indications, and they are currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia and their preclinical pipeline…More, including programs in amyotrophic lateral sclerosis and Huntington’s disease. Based in Philadelphia, PA, their company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct their discovery and IND-enabling preclinical work. Through this collaboration, they have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that they then pair with their deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance their robust pipeline of optimized gene therapies. As they work with speed and tenacity, they are always mindful of patients who may be able to benefit from their therapies.